Gesellschaftsrecht / M&A

Kapitalmarkt

Steuern

Finanzierungen und Anlageprodukte

IP / IT

Datenschutz

Arbeitsrecht und Vergütung für Führungskräfte

Wettbewerb

Regulierung

Healthcare / Life Sciences

Vectivio

Homburger News

Homburger and VectivBio

On May 22, 2023, VectivBio Holding AG (Nasdaq: VECT), Basel (Switzerland), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare gastrointestinal conditions, and Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced that they had entered into an agreement for Ironwood to launch an all-cash public tender offer to acquire all outstanding shares in VectivBio for USD 17 per share, with an estimated aggregate consideration of approximately USD 1 bn, net of VectivBio cash and debt. The acquisition price represents a premium of 80% relative to the volume-weighted average share price over the previous 90 trading days. The offer is subject to customary conditions and expected to close in mid-2023. VectivBio&#8217;s board of directors unanimously recommends the offer. Orbimed, Forbion and Versant Ventures, and VectivBio&#8217;s directors and officers jointly representing 28.6% of VectivBio&#8217;s shareholdings, entered into tender and support agreements in connection with, and in support of, the offer.
Homburger AG serves as legal and tax advisor to VectivBio on the transaction. The Homburger team includes Andreas Müller, Margrit Marti, Oliver Kneubühl, Francesco Bernasconi, Oliver Dalla Palma, Daniel Wenzinger and Carolina Rodriguez (all Corporate / M&amp;A), Lorenzo Togni (Capital Markets), Stefan Oesterhelt, Philippe Gobet and Kevin Müller (all Tax), Stefan Bindschedler (Financing and Investment Products), Luca Dal Molin (IP / IT; Data Protection), Angela Casey (Employment and Executive Compensation), and Richard Stäuber and Christoph Grüninger (Competition, Regulatory).

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Dufry_bw

On February 3, 2023, Dufry AG (SIX: DUFN) announced that it successfully closed the transfer of the 50.3% stake in Autogrill S.p.A (XMIL: AGL) held by Edizione S.p.A (through a wholly owned subsidiary) to Dufry.
Dufry will launch a mandatory public exchange offer for the remaining Autogrill shares (excluding treasury shares) at the same terms as Edizione and with a cash alternative of EUR 6.33 per Autogrill share.
Dufry expects to complete the full transaction including the mandatory exchange offer settlement by the end of Q2 2023.
Homburger acts as transaction counsel to Dufry. The Homburger team comprises Andreas Müller, Frank Gerhard, Oliver Kneubühl and Carlo Sulser (all Corporate / M&amp;A; Capital Markets), Jürg Frick, Eduard De Zordi, Alexander Wherlock and Nathalie Scherrer (all Financing and Investment Products / Capital Markets), Dieter Grünblatt and Reto Heuberger (both Tax), and Nicole Hilpert and Angela Casey (Employment and Executive Compensation).

Homburger advises Dufry on the successful closing of its strategic combination with Autogrill

HIG Capital

On November 3, 2022, H.I.G. Capital, a leading global investment firm with USD 52 bn of equity capital under management, announced that one of its affiliates has completed the acquisition of Celerion Holdings Inc., a leading full-service provider of outsourced clinical research services to the pharmaceutical industry.
The Homburger team comprised partner Andreas Müller, lead associate Sarah Chevalley, associate Oliver Kneubühl and junior associate Michele Fazari (all Corporate / M&amp;A), associates Joel Fink (IP / IT) and Kirsten Wesiak-Schmidt (Data Protection).

Oliver
Kneubühl

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Homburger advises Dufry on the successful closing of its strategic combination with Autogrill

Homburger advised H.I.G. Capital on its acquisition of Celerion

Swissair: Pflichtgemässe Verletzung von Kapitalschutzvorschriften?

Join the Team

Oliver Kneubühl

Karriere

Sprachen

Teams

OliverKneubühl

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Homburger advises Dufry on the successful closing of its strategic combination with Autogrill

Homburger advised H.I.G. Capital on its acquisition of Celerion

Swissair: Pflichtgemässe Verletzung von Kapitalschutzvorschriften?

Join the Team

Oliver Kneubühl

Karriere

Sprachen

Teams

Oliver
Kneubühl